EP1519747A4 - Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma) - Google Patents

Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma)

Info

Publication number
EP1519747A4
EP1519747A4 EP03721280A EP03721280A EP1519747A4 EP 1519747 A4 EP1519747 A4 EP 1519747A4 EP 03721280 A EP03721280 A EP 03721280A EP 03721280 A EP03721280 A EP 03721280A EP 1519747 A4 EP1519747 A4 EP 1519747A4
Authority
EP
European Patent Office
Prior art keywords
psma
monoclonal antibodies
human monoclonal
prostate specific
specific membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03721280A
Other languages
English (en)
French (fr)
Other versions
EP1519747A2 (de
Inventor
Yashwant M Deo
Robert Graziano
Debra Hudson
Eric H Holmes
William T Tino
Amelia Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of EP1519747A2 publication Critical patent/EP1519747A2/de
Publication of EP1519747A4 publication Critical patent/EP1519747A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03721280A 2002-01-28 2003-01-28 Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma) Withdrawn EP1519747A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5998902A 2002-01-28 2002-01-28
US59989 2002-01-28
PCT/US2003/002448 WO2003064606A2 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)

Publications (2)

Publication Number Publication Date
EP1519747A2 EP1519747A2 (de) 2005-04-06
EP1519747A4 true EP1519747A4 (de) 2006-03-29

Family

ID=27658271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03721280A Withdrawn EP1519747A4 (de) 2002-01-28 2003-01-28 Menschliche monoklonale antikörper gegen prostata-spezifisches membranantigen (psma)

Country Status (10)

Country Link
EP (1) EP1519747A4 (de)
JP (1) JP2005518789A (de)
KR (1) KR20040077889A (de)
CN (1) CN1652821A (de)
AU (1) AU2003224604B2 (de)
BR (1) BR0307216A (de)
CA (1) CA2474616A1 (de)
MX (1) MXPA04007262A (de)
NZ (1) NZ534687A (de)
WO (1) WO2003064606A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (de) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA Antikörper
KR101374514B1 (ko) * 2003-12-10 2014-03-13 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
EP2857418B1 (de) * 2004-02-06 2017-07-26 University of Massachusetts Antikörper gegen Clostridium difficile Toxine und ihre Verwendung
WO2005090407A1 (en) * 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
JP5112863B2 (ja) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス ヒト抗−ｋｉｒ抗体
ES2374603T3 (es) 2005-01-06 2012-02-20 Novo Nordisk A/S Agentes de unión a kir y procedimientos de uso de los mismos.
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
MX2007009878A (es) * 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
EP1726650A1 (de) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoklonale Antikörper und Einzelkettenantikörper Fragments gegen das zelloberflächen Prostataspezifische Membranantigen
ES2397973T3 (es) * 2006-03-14 2013-03-12 Cancer Targeted Technology Llc Inhibidores peptidomiméticos del PSMA, compuestos que los comprenden y métodos de utilización
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2727606A3 (de) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
EP4180458A1 (de) * 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Bispezifischer einkettiger psma x cd3-antikörper mit artenübergreifender spezifität
CN101891818B (zh) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 抗人前列腺特异性膜抗原胞外区单链抗体及其应用
EP2419451A4 (de) * 2009-04-14 2012-11-14 Proscan Rx Pharma Inc Antikörper gegen prostataspezifisches membranantigen
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
CN103333249A (zh) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2979219A1 (en) * 2015-03-10 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind psma
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
KR101704379B1 (ko) * 2015-10-27 2017-02-08 (주)알테오젠 항체-약물 접합체 및 그 제조방법
EP3434690A4 (de) 2016-03-23 2020-04-01 Seoul National University R&DB Foundation An hüllglykoprotein von schwerem-fieber-mit-thrombozytopenie-syndrom-virus bindender antikörper sowie verwendung dafür
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (de) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3-bindende proteine und verfahren zur verwendung
EP3897851A2 (de) 2018-12-17 2021-10-27 Revitope Limited Doppelimmunzell-engager
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
WO2021164692A1 (zh) * 2020-02-18 2021-08-26 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
US20230201366A1 (en) 2021-11-19 2023-06-29 Adc Therapeutics Sa Anti-psma conjugates
WO2024118940A1 (en) * 2022-12-01 2024-06-06 Twist Bioscience Corporation Anti-psma antibodies and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029457A2 (en) * 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
WO2001053353A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Recombinant antibodies to human interkleukin-1 beta
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004050850A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US20040175385A1 (en) * 1998-08-31 2004-09-09 The Regents Of The University Of Carlifornia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029457A2 (en) * 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
US20040175385A1 (en) * 1998-08-31 2004-09-09 The Regents Of The University Of Carlifornia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
WO2001053353A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Recombinant antibodies to human interkleukin-1 beta
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004050850A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONOVAN G P ET AL: "ANTIBODY AND VACCINE THERAPIES TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, 24 March 2001 (2001-03-24), pages 818, XP001204629, ISSN: 0197-016X *
HOLMES E H: "PSMA specific antibodies and their diagnostic and therapeutic use", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 3, 2001, pages 511 - 519, XP002988381, ISSN: 1354-3784 *
LIU H ET AL: "MONOCLONAL ANTIBODIES TO THE EXTRACELLULAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALSO REACT WITH TUMOR VASCULAR ENDOTHELIUM", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 17, 1 September 1997 (1997-09-01), pages 3629 - 3634, XP001080132, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
BR0307216A (pt) 2005-12-20
NZ534687A (en) 2007-10-26
CA2474616A1 (en) 2003-08-07
JP2005518789A (ja) 2005-06-30
MXPA04007262A (es) 2004-10-29
CN1652821A (zh) 2005-08-10
WO2003064606A3 (en) 2005-02-03
EP1519747A2 (de) 2005-04-06
AU2003224604B2 (en) 2007-06-14
WO2003064606A2 (en) 2003-08-07
KR20040077889A (ko) 2004-09-07

Similar Documents

Publication Publication Date Title
PL1851250T3 (pl) Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA)
TWI347951B (en) Therapeutic human anti-il-1r1 monoclonal antibody
IL161705A0 (en) Human monoclonal antibodies to dendritic cells
EP1633785A4 (de) Humane monoklonale antikörper gegen protektives antigen von bacillus anthracis
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
IL157274A0 (en) Human monoclonal antibodies to fc alpha receptor (cd89)
IL168304A (en) Human monoclonal antibodies against cd25
IL173273A0 (en) Modified human igf-1r antibodies
IL200604A0 (en) Human monoclonal antibodies against cd30
AU2003264009A8 (en) Humanized rabbit antibodies
AU2003295411A8 (en) Human monoclonal antibodies to heparanase
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
IL180789A0 (en) Human monoclonal antibodies against human il-4
AU2003265883A8 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
EP1618897A4 (de) Lipidmembran-struktur mit anti-mt-mmp-monoklonalem antikörper
AU2003277832A8 (en) Humanized tissue factor antibodies
IL172511A0 (en) Specific human antibodies
HK1079085A (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
SI1851250T1 (sl) Humano monoklonsko protitelo proti za prostato specifičnemu membranskemu antigenu (PSMA)
HK1104048A (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
EP1446416A4 (de) Tumorspezifische monoklonale antikörper
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.
GB0325391D0 (en) Human monoclonal antibodies
HK1087723A (en) Human monoclonal antibodies against bacillusanthracis protective antigen
GB0017139D0 (en) Human monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040820

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20060213

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079085

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060517

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1079085

Country of ref document: HK